Developing Synergistic Drug Combinations To Restore Antibiotic Sensitivity in Drug-Resistant Mycobacterium tuberculosis
Open Access
- 19 April 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (5)
- https://doi.org/10.1128/aac.02554-20
Abstract
Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent, accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We aimed to identify synergistic anti-TB drug combinations with the capacity to restore therapeutic efficacy against drug-resistant mutants of the causative agent, Mycobacterium tuberculosis. We investigated combinations containing the known translational inhibitors, spectinomycin (SPT) and fusidic acid (FA), or the phenothiazine, chlorpromazine (CPZ), which disrupts mycobacterial energy metabolism. Potentiation of whole-cell drug efficacy was observed in SPT-CPZ combinations. This effect was lost against an M. tuberculosis mutant lacking the major facilitator superfamily (MFS) efflux pump, Rv1258c. Notably, the SPT-CPZ combination partially restored SPT efficacy against an SPT-resistant mutant carrying a g1379t point mutation in rrs, encoding the mycobacterial 16S rRNA. Combinations of SPT with FA, which targets the mycobacterial elongation factor G, exhibited potentiating activity against wild-type M. tuberculosis. Moreover, this combination produced a modest potentiating effect against both FA-monoresistant and SPT-monoresistant mutants. Finally, combining SPT with the frontline anti-TB agents, rifampicin (RIF) and isoniazid, resulted in enhanced activity in vitro and ex vivo against both drug-susceptible M. tuberculosis and a RIF-monoresistant rpoB S531L mutant. These results support the utility of novel potentiating drug combinations in restoring antibiotic susceptibility of M. tuberculosis strains carrying genetic resistance to any one of the partner compounds.Keywords
Funding Information
- Novartis Research Foundation
- Strategic Health Innovations Partnerships Unit of the South African Medical Research Council
- Carnegie Mellon Scholarship Awards
- Norges Forskningsråd
- South African Medical Research Council
- University of Cape Town
This publication has 68 references indexed in Scilit:
- The Pharmaco –, Population and Evolutionary Dynamics of Multi-drug Therapy: Experiments with S. aureus and E. coli and Computer SimulationsPLoS Pathogens, 2013
- Drug repurposing from an academic perspectiveDrug Discovery Today: Therapeutic Strategies, 2012
- Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-Throughput ScreenAntimicrobial Agents and Chemotherapy, 2011
- Phenotypic Landscape of a Bacterial CellCell, 2011
- Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among Staphylococcus spp. Isolated in North America and Australia, 2007-2008Antimicrobial Agents and Chemotherapy, 2010
- Optimal Drug Synergy in Antimicrobial TreatmentsPLoS Computational Biology, 2010
- The Structure of the Ribosome with Elongation Factor G Trapped in the Posttranslocational StateScience, 2009
- High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infectionsProceedings of the National Academy of Sciences of the United States of America, 2007
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997
- Effect of Spectinomycin Use on the Prevalence of Spectinomycin-Resistant and of Penicillinase-ProducingNeisseria GonorrhoeaeThe New England Journal of Medicine, 1987